Clinical Trial Update: Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating the safety and efficacy of blocking IL-4 with Pascolizumab in patients receiving standard therapy for pulmonary tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis Pulmonary

Drugs mentioned

• Pascolizumab (anti-IL-4 monoclonal antibody)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Tuberculosis, Pulmonary | Phase 2 | Status: UNKNOWN